bioihbjkbjnl/mcl2 huggingface dataset:
Comparison of Intra-articular Dexmedetomidine and Magnesium in Postoperative Pain
Condition: Postoperative Pain; Intra-articular Injection; Dexmedetomidine; Magnesium Sulfate
MeSH terms: Pain, Postoperative
Intervention: Precedex; Magnesium Sulfate
Intervention description: 10 ml of Bupivacaine ve 50mcg Dexmetedomidin mixture will be injected intraarticularly at the end of the surgery.; 10 ml of Bupivacaine ve magnesium sulfate mixture will be injected intraarticularly at the end of the surgery.
Intervention MeSH terms: Magnesium Sulfate; Dexmedetomidine; Bupivacaine
Phase: Phase 4
Study type: Interventional
Primary purpose: Supportive Care
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Outcomes Assessor)
Enrollment: 62.0
Sex: All
Minimum age: 18 Years
Maximum age: 65 Years
Healthy volunteers: No
Keywords: Analgesia; Anesthesia; Arthroscopy; Bupivacaine; Dexmedetomidine; Injections, Intra-Articular; Magnesium; Pain, Postoperative

Summary:

      Arthroscopic meniscus surgeries are the most frequent orthopedic procedures. The objective of
      the study is to compare the effects of intraarticular local anesthetic and adjuvant
      (dexmedetomidine vs magnesium) combinations in postoperative pain and analgesic requirement.
      The investigators' hypothesis is adjuvants added to the local anesthetics decreases the total
      local anesthetic dose, provides more effective pain relief according to local anesthetic
      only, and decreases the postoperative systemic non-steroidal analgesic and opioid doses.
    

Eligibility criteria:

        Inclusion Criteria:

          -  age >18, <65

          -  scheduled for elective knee arthroscopy under spinal anesthesia

          -  ASA I and ASA II

        Exclusion Criteria:

          -  age <18 and >65

          -  patients who received general anesthesia

          -  diabetes

          -  refusal of the patient

          -  known allergy to the specified drugs
Effects of Intramuscular (IM) Oxytocin on Pupil Diameter and Heart Rate Variability (HRV)
Condition: Chronic Pain Due to Injury
MeSH terms: Chronic Pain
Intervention: Oxytocin; Placebo
Intervention description: Oxytocin 10 IU; Placebo
Intervention MeSH terms: Oxytocin
Phase: Phase 4
Study type: Interventional
Primary purpose: Basic Science
Allocation: Randomized
Intervention model: Crossover Assignment
Intervention model description: Double blinded crossover treatment with oxytocin and placebo (saline)
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Masking description: Participant, Investigator, and outcomes assessor will be blinded. The Research Pharmacist will prepare the study medication and hold the randomization.
Enrollment: 22.0
Sex: All
Minimum age: 18 Years
Maximum age: 66 Years
Healthy volunteers: Accepts Healthy Volunteers
Keywords: Healthy Volunteer; Oxytocin; Pupillometry

Summary:

      The goal of this study is to test the effects of oxytocin on heart rate variability and pupil
      diameter, both of which have subtle effects on the activity rate of the autonomic nervous
      system.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Male or female > 18 and < 66 years of age,

          -  Body Mass Index (BMI) <40

          -  Generally in good health as determined by the Principal Investigator based on prior
             medical history

          -  Normal blood pressure and resting heart rate without medication

        Exclusion Criteria:

          -  Hypersensitivity, allergy, or significant reaction to any ingredient of Pitocin®

          -  Any disease, diagnosis, or condition (medical or surgical) that, in the opinion of the
             Principal Investigator, would place the subject at increased risk

          -  Women who are pregnant (positive result for serum pregnancy test at screening visit),

          -  Women who are currently nursing or lactating, women that have been pregnant within 2
             years.

          -  Neuropathy, chronic pain, diabetes mellitus, or taking benzodiazepines or pain
             medications on a daily basis.

          -  Previous eye surgery, eye medications, cataracts
Pressure Ulcer Healing With Microcyn
Condition: Pressure Ulcer; Spinal Cord Injuries
MeSH terms: Spinal Cord Injuries; Pressure Ulcer; Ulcer
Intervention: Microcyn; Sterile saline
Intervention description: Microcyn is liberally sprayed on wound and permitted to remain on wound which will then be dressed with gauze that is moistened with Microcyn twice daily for the earlier of total wound closure or Week 24; Sterile saline is liberally sprayed on wound and permitted to remain on wound which will then be dressed with gauze that is moistened with sterile saline twice daily for the earlier of total wound closure or Week 24
Phase: Phase 4
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Enrollment: 65.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No
Keywords: Spinal cord injuries; Pressure ulcer

Summary:

      The purpose of this study is to test how well Microcyn™ works on Stage 3 and Stage 4 pressure
      ulcers compared to sterile saline among persons with spinal cord injury.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Age > 17 years

          -  Persons with spinal cord injury

          -  Having Stage III/IV pressure ulcer(s)

          -  Able to fulfill all obligations of the study

        Exclusion Criteria:

          -  Pressure ulcers scheduled for surgical closure within 14 days

          -  Use of any immunosuppressant medications within 30 days of screening

          -  Having conditions that put the subject at significant risk

          -  Medically unstable or has a life expectancy of less than 12 months

          -  Current enrollment in an investigational drug or device study or participation in such
             a study within the last 30 days

          -  Pregnant women
Neuroimaging the Expectancy Versus Pharmacotherapy Effect of Adderall on Cognitive Performance
Condition: Expectancy Versus Pharmacotherapy Effect of Adderall
Intervention: Adderall; Placebo
Intervention description: Participants will be administered Adderall; Participants will be administered placebo
Intervention MeSH terms: Adderall
Phase: Phase 4
Study type: Interventional
Primary purpose: Health Services Research
Allocation: Randomized
Intervention model: Factorial Assignment
Intervention model description: 2 X 2, within-subjects, balanced placebo design
Masking: Double (Participant, Investigator)
Masking description: This will be a double-blind study. Research assistants will administer capsules, and based on package labeling, tell the participant if they are being administered Adderall or placebo. However, researchers and participants will be blind to which medication is actually being administered.
Enrollment: 4.0
Sex: All
Minimum age: 18 Years
Maximum age: 24 Years
Healthy volunteers: Accepts Healthy Volunteers

Summary:

      The purpose of this balanced-placebo design study is to pilot a larger study to further
      explore the current evidence that stimulant medications are not cognitive enhancers, despite
      this rampant belief in young adults. While the lack of cognitive enhancement from stimulant
      medication has been documented in prior research, this study is the first to utilize
      neuroimaging technology to examine brain regions activated during neurocognitive tasks when
      participants believe they have been administered stimulant medication or placebo.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Age (18-24)

          -  College student with at least average IQ

          -  Willingness to standardize caffeine intake to 100 mg on day of study

        Exclusion Criteria:

          -  Attention Deficit/Hyperactivity Disorder (ADHD)

          -  First degree relative with ADHD

          -  Unwillingness to comply with caffeine specifications

          -  Regular use of Adderall

          -  Pregnant/breastfeeding

          -  History of substance use disorders

          -  Illicit stimulant use within the last year

          -  Contraindications to stimulants (i.e., tics, Tourette's, cardiac disease,
             hypertension)

          -  Uncontrolled medical illness

          -  Active contagious infection
Prevention of Surgical Site Infections: Effectiveness of Nasal Povidone-Iodine and Nasal Mupirocin
Condition: Surgical Site Infection
MeSH terms: Infections; Communicable Diseases; Surgical Wound Infection
Intervention: mupirocin calcium ointment, 2%; 3M Skin and Nasal Antiseptic
Intervention description: Approximately one-half of the ointment from the single-use tube should be applied into 1 nostril and the other half into the other nostril twice daily (morning and evening) for 5 days.
After application, the nostrils should be closed by pressing together and releasing the sides of the nose repetitively for approximately 1 minute. This will spread the ointment throughout the nares.; The solution is applied to for 30 seconds to each nostril twice for a total of 2 minutes. The solution is applied by rotating the applicator around the circumference of the nostril for 15 seconds and then rotating the applicator in the anterior nares for 15 seconds.
Intervention MeSH terms: Povidone-Iodine; Anti-Infective Agents, Local; Mupirocin; Povidone; Calcium
Phase: Phase 4
Study type: Interventional
Primary purpose: Prevention
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Enrollment: 1874.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No

Summary:

      We hypothesize the application of mupirocin or povidone-iodine to the nares is equally
      effective in short term Staphylococcus aureus(SA)suppression. Our overall study objective is
      to measure the rate of deep and superficial Surgical Site Infections (SSIs) after primary
      hip, knee, shoulder and elbow arthroplasty surgery and primary spinal fusion surgery
      requiring implantation of prosthetic material, when the patient receives either nasal
      mupirocin or nasal povidone-iodine prior to surgery.

      Secondary study objectives include:

        1. Measure hospital length of stay and re-admission rates in the mupirocin and
           povidone-iodine groups.

        2. Measure adverse events related to mupirocin and povidone-iodine.

        3. Measure rate of SA resistance to mupirocin.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Primary arthroplasty or spinal fusion surgery

          -  Age greater than 18 years

        Exclusion Criteria:

          -  Revision arthroplasty

          -  Revision spinal fusion surgery

          -  Primary spine surgery without implantation of prosthetic material

          -  Allergy to mupirocin

          -  Allergy to povidone-iodine

          -  Pregnancy

          -  Breastfeeding
The Effect of LINAGLIPTIN on Inflammation, Oxidative Stress and Insulin Resistance in Obese Type 2 Diabetes Subjects
Condition: Type 2 Diabetes
MeSH terms: Diabetes Mellitus; Diabetes Mellitus, Type 2; Insulin Resistance; Inflammation
Intervention: Linagliptin; Placebo
Intervention description: 5 mg daily oral tablets of linagliptin; matching placebo giving orally daily
Intervention MeSH terms: Linagliptin
Phase: Phase 4
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Enrollment: 40.0
Sex: All
Minimum age: 20 Years
Maximum age: 80 Years
Healthy volunteers: No

Summary:

      This is a single center, prospective randomized double blind, parallel and placebo controlled
      study to evaluate oxidative stress and inflammation before and after treatment with
      linagliptin for 12 weeks. We will also, testing whether Linagliptin is an insulin sensitizer.
    

Eligibility criteria:

        Inclusion Criteria:

        Age 20-80 years inclusive. Type 2 diabetes BMI ≥30 kg/m2 Subjects on statins, ACE
        inhibitors, thiazolidinediones and antioxidants will be allowed as long as they are on
        stable doses of these compounds and the dosage in not changed during the course of study.

        HbA1c ≤ 8.0%

        Exclusion Criteria:

        - Use of GLP-1 agonists or DPP-IV therapy in the last 3 months. History of Pancreatitis.
        Risk for pancreatitis, i.e., history of gallstones, alcohol abuse, and
        hypertriglyceridemia.

        Subjects who are taking antiplatelet or anticoagulant medications will be excluded from the
        fat biopsy portion of the study.

        Coronary event or procedure (myocardial infarction, unstable angina, coronary artery
        bypass, surgery or coronary angioplasty) in the previous four weeks Hepatic disease (liver
        function tests more than 3 times the upper limit of normal) Renal impairment (serum eGFR
        <30 ml/min) Any other life-threatening, non-cardiac disease Uncontrolled hypertension (BP >
        160/100 mm of Hg) Congestive Heart Failure class III or IV. Use of an investigational agent
        or therapeutic regimen within 30 days of study Participation in any other concurrent
        clinical trial
VAccination to Improve Clinical outComes in Heart Failure Trial: a Feasibility Study (VACC-HeFT)
Condition: Chronic Heart Failure
MeSH terms: Heart Failure
Intervention: Influenza vaccine
Intervention description: Influenza vaccine
Phase: Phase 4
Study type: Interventional
Primary purpose: Prevention
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Enrollment: 48.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No

Summary:

      A multi-center, prospective, randomized, open-label blinded-endpoint trial in patients with
      heart failure will be conducted; 20 will be assigned to the standard dose vaccine dose and 20
      patients to high dose influenza vaccine. Post-vaccine antibody measurements will be assessed,
      as well as tolerability differences between groups.
    

Eligibility criteria:

        Inclusion Criteria:

          1. Adults > 18 years old

          2. Able to give informed consent

          3. Systolic or diastolic dysfunction

          4. Previously or currently symptomatic heart failure

          5. Stable on current heart failure drug therapy regimen for > 30 days and no change in
             heart failure drug therapy regimen on day of enrollment

          6. Hospitalization (for any reason) in last 12 months

          7. Received influenza vaccination the prior season

        Exclusion Criteria:

          1. History of allergic reaction or adverse event to influenza vaccine

          2. Documented severe allergy to egg products

          3. Unwilling or unable to give consent

          4. Moderate to severe acute febrile illness at baseline

          5. Immunologic conditions that may affect immune responses per clinical judgment of the
             investigators

          6. Use of immunosuppressants or immunomodulating therapies within 3 months of the study,
             including prednisone, cyclosporine, tacrolimus, methotrexate, azathioprine,
             mycophenolate mofetil, cyclophosphamide, and injectable interferons

          7. Participation in a clinical trial within 30 days

          8. Absence for more than 7 consecutive days during the surveillance period
LARC Forward Contraceptive Counseling at MHCC
Condition: Contraception
Intervention: Long Acting Reversible Contraception (LARC); Referral for Long Acting Reversible Contraception (LARC); Prescription for Short-Acting Hormonal Contraception
Intervention description: Same day LARC placement (intervention) of Mirena, Skyla, Paragard, Implanon; Referral to local clinic for LARC placement of choice (Mirena, Skyla, Paragard, Implanon, etc.); Participants who chose a short-acting hormonal method (e.g. contraceptive pills, ring, or patch) will receive a prescription to the pharmacy of their choice
Phase: Phase 4
Study type: Interventional
Primary purpose: Health Services Research
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Enrollment: 3.0
Sex: Female
Minimum age: 17 Years
Maximum age: 30 Years
Healthy volunteers: Accepts Healthy Volunteers
Keywords: LARC; IUD; Contraceptive Implant; Contraception; Community college

Summary:

      This prospective randomized controlled study will evaluate if Long Acting Reversible
      Contraceptive (LARC) forward counseling in combination with same-day LARC placement increases
      overall LARC uptake within a community college population compared to LARC forward counseling
      and referral to a secondary clinic for LARC placement. The study will be conducted at Mount
      Hood Community College (MHCC) in Oregon. Participants will be enrolled into three groups. All
      groups will receive the same standardized contraceptive counseling ("LARC forward
      counseling") and participants will be able to choose between a LARC method and short-acting
      method of birth control.
    

Eligibility criteria:

        Inclusion Criteria:

          -  English or Spanish-speaking women.

          -  17-30 years of age.

          -  Currently enrolled in a 2-year certificate program at Mount Hood Community College.

          -  At risk for pregnancy (sexually active with men or anticipate becoming sexually active
             in the next 6 months).

          -  Do not desire pregnancy within the next 12 months.

          -  No contraindications to LARC according to the Center for Disease Control and
             Prevention medical eligibility criteria (CDC MEC)

        Exclusion Criteria:

          -  Women who are not currently sexually active with men and who do not anticipate
             becoming sexually active with a male partner in the next 6 months.

          -  Women who have had a tubal ligation or other sterilization procedure.

          -  Women who desire pregnancy within the next 12 months.

          -  Women currently already using a LARC method for contraception.
Post-marketing Clinical Study of Rebamipide in Patients With Gastric Ulcer
Condition: Stomach Ulcer
MeSH terms: Stomach Ulcer; Ulcer
Intervention: Rebamipide
Intervention MeSH terms: Rebamipide
Phase: Phase 4
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double
Enrollment: 301.0
Sex: All
Minimum age: 20 Years
Healthy volunteers: No

Summary:

      To examine the efficacy of continued administration of rebamipide following bacteria
      eradication therapy in patients with H. pylori-positive active gastric ulcer in a
      placebo-controlled, double-blind study
    

Eligibility criteria:

        Inclusion Criteria:

          1. Patients aged 20 years or older at time of consent

          2. H. pylori-positive patients meeting both of the following criteria:• Assessed as H.
             pylori-positive by rapid urease test and/or 13C-urea breath test at pre-study
             examination, • Assessed as H. pylori-antibody-positive by urine-based test after
             obtaining informed consent

          3. Patients endoscopically diagnosed with gastric ulcer meeting the following criteria:•
             Active (A1- or A2-stage by Sakita/Miwa classification）, • Solitary, • Longitudinal
             diameter: ->5 mm

          4. Patients who have not received proton pump inhibitors (PPIs), antibacterial agents, or
             antiprotozoal agents within 1 week prior to endoscopy

        Exclusion Criteria:

          1. Patients who have previously received H. pylori eradication therapy

          2. Patients with acute gastric ulcer

          3. Patients with linear ulcer

          4. Patients with complication of duodenal ulcer (excluding cicatrix)

          5. Patients who have undergone upper-GI tract or vagal nerve resection

          6. Patients who are unsuitable for pharmacotherapy, e.g., with perforation or pyloric
             stenosis

          7. Patients with gastric ulcer considered likely to induce massive hemorrhage (e.g., with
             obviously exposed blood vessels at lesion sites)

          8. Patients with a history of amoxicillin shock

          9. Patients with infectious mononucleosis

         10. Patients with severe renal disorders

         11. Patients with a history of hypersensitivity to penicillins, clarithromycin,
             lansoprazole, or rebamipide

         12. Patients who have been treated with drugs contraindicated to clarithromycin, such as
             terfenadine, cisapride, and pimozide

         13. Patients who are pregnant, possibly pregnant, lactating, or who desire to become
             pregnant during the study

         14. Patients who are otherwise judged inappropriate for inclusion in the study by the
             investigator or subinvestigator
The Role of Estrogen in Luteinizing Hormone Surge and Ovulation
Condition: Ovulation Disorder; Ovarian Cysts
MeSH terms: Ovarian Cysts
Intervention: Letrozole
Intervention description: Letrozole administered daily through the time of ovulation.
Intervention MeSH terms: Letrozole
Phase: Phase 4
Study type: Interventional
Primary purpose: Diagnostic
Allocation: Non-Randomized
Intervention model: Single Group Assignment
Masking: Triple (Care Provider, Investigator, Outcomes Assessor)
Enrollment: 10.0
Sex: Female
Minimum age: 18 Years
Maximum age: 40 Years
Healthy volunteers: Accepts Healthy Volunteers

Summary:

      The purpose of the study is to establish that sustained estrogen levels are the driving force
      for the LH surge, and are thereby necessary for ovulation to occur. We predict that by
      reducing levels of circulating estrogen, letrozole, an aromatase inhibitor, will inhibit
      ovulation from occurring.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Patient having regular menstrual cycles between 26-30 days

          -  Ages 18-40

          -  Patient must not be sexually active during the study period, or if so must be using a
             reliable form of non-hormonal birth control including tubal ligation or vasectomy,
             non-hormonal intrauterine contraceptive device (IUD), or condoms with spermicide.

          -  Willing to participate in study and available for all monitoring visits.

          -  IRB consent

        Exclusion Criteria:

          -  Patient must NOT have used hormonal contraception three months or less prior to study.

          -  Irregular menstrual cycles (<26 days or >30 days within the last 6 months.

          -  Untreated thyroid dysfunction or hyperprolactinemia

          -  Pregnancy (current or within 3 months) or breastfeeding

          -  Allergy or contraindication to letrozole